PDF factsheet
      Z

poly ADP-ribose polymerase (PARP) inhibitor in ovarian cancer for patients with BRCA mutation, clinical trials results

niraparib versus placebo
ENGOT-OV16/NOVA gBRCA, 2017
NCT01847274
niraparib (300 mg) once daily as maintenance treatment
versus
placebo
patients with platinum-sensitive, recurrent ovarian cancer with germline BRCA mutation double-blind
olaparib versus placebo
SOLO2/ENGOT-Ov21,
NCT01874353
olaparib 300 mg in two 150 mg tablets, twice daily
versus
placebo
patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutationdouble-blind
international

  Options


in first

in second

  Filter